Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis-Reference-Cited by-同舟云学术

Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis

Published:2022 Issue:14 Volume:10 Page:3878-3891
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Wang Huangwei¹²,Shang Jun³⁴,He Zhesheng¹,Zheng Miaomiao¹²,Jia Huiju¹²,Zhang Yaning³,Yang Wenzhi²,Gao Xueyun⁵^ORCID,Gao Fuping¹^ORCID

Affiliation:

1. CAS Key Laboratory for the Biological Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China

2. School of Pharmacy, Hebei University, Baoding 071002, China

3. Linfen People's Hospital, Shanxi 041000, China

4. Tianjin Medical University General Hospital, Tianjin 300052, China

5. Department of chemistry and biology, Beijing University of Technology, Beijing 100124, China

Abstract

A dual peptide nanoparticles platform, including the antigen peptide of the primary signal and inhibitory peptide of co-stimulatory signal for T-cell activation, trigger antigen-specific immune tolerance to treat experimental autoimmune encephalomyelitis (EAE).

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hebei Province

Natural Science Foundation of Beijing Municipality

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D2BM00444E

Reference44 articles.

1. Pathology of multiple sclerosis and related inflammatory demyelinating diseases